Published in Healthcare Mergers, Acquisitions and Ventures Week, February 5th, 2005
Recent corporate developments include:
1) Expected product revenues of $9.6 million, which represents 46% growth as compared to the third quarter of last year and represents the second highest quarterly revenue in company history.
2) Expected net loss of $.01 per share, compared to a net loss of $.09 per share in the same quarter last year;
3) Record sales growth of 69% in Europe versus prior year and the highest quarterly...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.